Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- January31 2005
- Volume 12
- Issue 2
News You Can Use: Doctors on Trial
Advertisement
According to Jury Verdict Research (www.juryverdictresearch.com), plaintiffs continue to lose the majority of cases that go to a jury. However, overall, physicians are losing more cases than in years past. And juries are compensating plaintiffs more generously; the average judgment is now $1,010,858. The following is the percentage of plaintiffs who win jury judgments for various malpractice cases:
Articles in this issue
about 18 years ago
Doctors Have to Believe in Miraclesabout 18 years ago
Consider Your Body Your Greatest Assetabout 18 years ago
Yangtze: The River of Heaven and the Heart of Chinaabout 18 years ago
Cinema Consults: HARRY POTTER AND THE PRISONER OF AZKABANabout 18 years ago
Pair Safety with Growth Through Hybridsabout 18 years ago
It Pays to Maintain the Right Attitudeabout 18 years ago
Test Your Luck with Timing the Marketabout 18 years ago
Stretch Your Wealth with Inherited IRAsabout 18 years ago
The Malpractice Plague Continues to Rageabout 18 years ago
Explore Options for Malpractice ReliefAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5